三星醫療(601567.SH):擬以1.8億元收購武漢明州康復醫院100%股權
格隆匯3月27日丨三星醫療(601567.SH)公佈,公司下屬子公司寧波奧克斯康復醫療投資管理有限公司(“康復投資”)擬以自有資金1.8億元收購寧波開雲華風股權投資合夥企業(有限合夥)(“開雲華風”)、寧波眾善投資管理合夥企業(有限合夥)(“眾善投資”)分別持有的武漢明州康復醫院有限公司(“武漢明州康復”)70%、30%股權。
公司此次收購武漢明州康復股權,符合公司持續發展的戰略需求,有利於完善公司的產業佈局,優化產業結構,提升公司在醫療服務產業的整體實力和市場競爭優勢,有助於增強公司的盈利能力,對於公司長遠發展具有重要意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.